CN112791080A - Application of resveratrol dimer TVN in the preparation of medicaments for the treatment of osteoarthritis - Google Patents
Application of resveratrol dimer TVN in the preparation of medicaments for the treatment of osteoarthritis Download PDFInfo
- Publication number
- CN112791080A CN112791080A CN202110080192.1A CN202110080192A CN112791080A CN 112791080 A CN112791080 A CN 112791080A CN 202110080192 A CN202110080192 A CN 202110080192A CN 112791080 A CN112791080 A CN 112791080A
- Authority
- CN
- China
- Prior art keywords
- tvn
- osteoarthritis
- cartilage
- group
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 33
- FQWLMRXWKZGLFI-YVYUXZJTSA-N (-)-trans-epsilon-viniferin Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC2=C1[C@@H](C=1C=C(O)C=C(O)C=1)[C@H](C=1C=CC(O)=CC=1)O2 FQWLMRXWKZGLFI-YVYUXZJTSA-N 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title claims abstract description 11
- 238000011282 treatment Methods 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 9
- 210000001188 articular cartilage Anatomy 0.000 claims abstract description 8
- 102000055008 Matrilin Proteins Human genes 0.000 claims abstract description 7
- 108010072582 Matrilin Proteins Proteins 0.000 claims abstract description 7
- 230000010072 bone remodeling Effects 0.000 claims abstract description 6
- 230000015556 catabolic process Effects 0.000 claims abstract description 5
- 238000006731 degradation reaction Methods 0.000 claims abstract description 5
- 208000006386 Bone Resorption Diseases 0.000 claims abstract description 4
- 230000024279 bone resorption Effects 0.000 claims abstract description 4
- 230000001934 delay Effects 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims description 11
- 230000008355 cartilage degradation Effects 0.000 claims description 6
- 230000002926 anti-osteoarthritic effect Effects 0.000 claims description 3
- 210000000845 cartilage Anatomy 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 3
- 206010007710 Cartilage injury Diseases 0.000 abstract description 2
- 230000002441 reversible effect Effects 0.000 abstract description 2
- 206010065687 Bone loss Diseases 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 16
- 210000005065 subchondral bone plate Anatomy 0.000 description 12
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 102100027995 Collagenase 3 Human genes 0.000 description 5
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 5
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 5
- 210000000629 knee joint Anatomy 0.000 description 5
- 230000003902 lesion Effects 0.000 description 4
- 210000004417 patella Anatomy 0.000 description 4
- 229950003937 tolonium Drugs 0.000 description 4
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 230000008422 cartilage matrix degradation Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000270923 Hesperostipa comata Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000005137 Joint instability Diseases 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 1
- 235000018365 Momordica dioica Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000000426 patellar ligament Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开白藜芦醇二聚体TVN在制备治疗骨性关节炎药物中的应用。所述TVN通过抑制骨吸收和骨重塑，改善骨流失，保护关节软骨；并且通过改善软骨退化和软骨损伤延缓骨性关节炎的进程；同时，通过维持软骨基质的稳态来抑制软骨基质的降解，可用于开发能够延缓或逆转骨性关节炎进程的药物。The invention discloses the application of resveratrol dimer TVN in preparing medicine for treating osteoarthritis. The TVN improves bone loss and protects articular cartilage by inhibiting bone resorption and bone remodeling; and delays the progression of osteoarthritis by improving cartilage degeneration and cartilage damage; at the same time, it inhibits cartilage matrix by maintaining the homeostasis of cartilage matrix. Degradation can be used to develop drugs that can slow or reverse the progression of osteoarthritis.
Description
Technical Field
The invention relates to a traditional Chinese medicine technology, in particular to an application of resveratrol dimer TVN in preparing a medicine for treating osteoarthritis.
Background
Osteoarthritis (OA) is the most common age-related degenerative disease, with the incidence of OA in older adults over 65 years of age reaching over 37%, with OA in older adults over 75 years of age reaching over 80%, with women having a 2-fold higher incidence of OA than men. It is characterized by synovial inflammation, cartilage degradation, cartilage matrix degradation, subchondral bone reconstruction and osteophyte formation, ultimately leading to joint pain and dysfunction. The symptoms of joint pain, swelling, stiffness, joint movement limitation and the like which are slowly progressed are frequently clinically manifested, and severe patients are manifested by joint deformity and joint function loss, which are main sources of social and economic costs, seriously affect the movement function of patients and reduce the life quality. OA is a multifactorial disease, the major causative factors including: age, sex, obesity, trauma, genetic and metabolic factors, the pathogenesis of which has not been established to date, and thus no established protocol exists for the prevention and treatment of OA. The current drugs for treating OA are mainly non-steroidal anti-inflammatory drugs, steroids, and the like. Joint replacement is an effective treatment for symptomatic end-stage disease, but the effect is not ideal and the life of the prosthesis is limited. Therefore, the emphasis on the study of osteoarthritis has shifted to disease prevention and treatment of early osteoarthritis.
The resveratrol dimer, (7R,8R) -Trans-delta-viniferin, TVN for short, has the following structural formula:
the compound is a natural product separated from grapes, and can also be used for carrying out biotransformation on resveratrol by balsam pear peroxidase to obtain TVN. The patent CN 201310238137.6 shows that the TVN can obviously reduce mouse hyperglycemia caused by cane sugar through pharmacodynamic experiments. On this basis, the applicants further investigated the biological activity of TVN against osteoarthritis.
Disclosure of Invention
The purpose of the invention is as follows: in view of the above prior art, the present application provides an application of resveratrol dimer TVN in the preparation of a medicament for treating osteoarthritis.
The technical scheme is as follows: the invention discloses an application of resveratrol dimer TVN in preparing a medicament for treating osteoarthritis.
The resveratrol dimer TVN can delay or reverse the progress of osteoarthritis.
Further, the resveratrol dimer TVN can inhibit bone remodeling by inhibiting bone resorption, and relieve the progress of osteoarthritis.
Further, the resveratrol dimer TVN exerts an anti-osteoarthritis effect by alleviating cartilage degradation.
Further, the resveratrol dimer TVN can protect articular cartilage by inhibiting the degradation of cartilage matrix and delay the progression of osteoarthritis.
Has the advantages that: experiments prove that the resveratrol dimer TVN can inhibit bone remodeling by inhibiting bone absorption and relieve the progress of osteoarthritis; can relieve cartilage degradation and play a role in resisting osteoarthritis; can inhibit the degradation of cartilage matrix to protect articular cartilage and delay the process of osteoarthritis, so that the resveratrol dimer TVN can be used for developing related anti-osteoarthritis medicines.
Drawings
FIG. 1 is a BV/TV quantitative analysis of the effect of TVN on bone density of mice modeled by ACLT;
FIG. 2 is a graph showing the effect of Tb.N on the number of trabeculae in ACLT-modeled rats;
FIG. 3 is a graph showing the effect of Tb.Th on the trabecular bone thickness of ACLT-modeled rats;
FIG. 4 is a graph showing the effect of Tb.Sp in quantitative analysis of TVN on the trabecular bone resolution of ACLT-modeled rats;
FIG. 5 is a graph showing the effect of safranin fast green on the structural changes of cartilage and subchondral bone in ACLT-modeled rats;
FIG. 6 is a graph showing toluidine blue to evaluate the protective effect of TVN on subchondral bone of ACLT-modeled rats;
FIG. 7 is a graph showing the effect of OARSI in the quantitative analysis of TVN on cartilage degradation in ACLT-modeled rats;
FIG. 8 is MMP13, and Collagen II immunohistochemistry was performed to evaluate the effect of TVN on cartilage matrix degradation in ACLT-modeled rats.
Detailed Description
The present application will be described in detail with reference to specific examples.
The TVN used in the examples was prepared by the method described in patent CN 201310238137.6.
Example 1 establishment of anterior cross ligament resection (ACLT) animal model
All animal experimental procedures were in compliance with the approval of the animal ethics committee of the university of chinese medical science. 50 SPF-grade SD male rats of 180-. Then, 40 rats were subjected to ACLT modeling simulation OA, the specific protocol: the rat is anesthetized and then fixed, hairs near the knee joint of the right leg of the rat are removed completely, the hairs are wiped by alcohol, the sterile environment is guaranteed as far as possible, a longitudinal incision with the length of about 1cm is made on the inner side skin beside the patella of the rat by using a surgical knife, then the knee joint is exposed, the patella and the patellar ligament are dislocated towards the outer side gently, the knee joint capsule is opened, the anterior cruciate ligament can be observed clearly by naked eyes, the fat pad is poked slightly by using micro forceps, and the anterior cruciate ligament is cut. Sterile normal saline is dripped on the surface of the articular cartilage to avoid the articular fluid attached to the surface of the articular cartilage from being completely dried in the operation process. Then the patella is reset, the muscle is sewed by 4-0 absorbable suture, the iodophor is sterilized, and then the patella is sewed by aseptic needle and thread. Penicillin is given 10 ten thousand U/time for three consecutive days after molding, once a day.
EXAMPLE 2TVN prophylaxis treatment of osteoarthritis
One week after molding, 50 rats were randomly grouped as: normal group, ACLT surgical model group, sodium hyaluronate positive control group (2.5 mL: 25mg), TVN (0.5mg/kg), TVN (1mg/kg), 10 pieces per group. TVN was dissolved with 40% PEG400, and administered by knee injection at doses of 0.5mg/kg and 1mg/kg, 50. mu.L each, for 5 weeks, 2 times per week. The sodium hyaluronate group was injected with 50. mu.L each time for 5 weeks, 1 time each time. The model group was injected with the same volume of 40% PEG 400. After 5 weeks of administration, the rats were euthanized and the right leg knee joint was fixed in 4% paraformaldehyde for later histological evaluation.
Example 3Micro-CT evaluation of the Effect of TVN on bone Density and subchondral bone microstructure in rats
The specimens were scanned using a Scanco viva CT 80 instrument. Setting parameters: resolution, 21 μm; voltage, 70 kV; current, 113 μ A. The parameters tested were: bone density (BV/TV), trabecular bone separation (Tb.Sp), trabecular bone number (Tb.N), trabecular bone thickness (Tb.Th).
BV/TV results are shown in FIG. 1, the model group (0.5072 + -0.03585) was significantly lower (P <0.001) than the normal group (0.6720 + -0.01821), significantly lower (P <0.001) than the sodium hyaluronate group (0.6264 + -0.04524), and significantly lower (P <0.001) than the TVN (0.5mg/kg) group (0.5767 + -0.03377) and TVN (1mg/kg) group (0.6229 + -0.03187). Tb.n and tb.th gave results consistent with BV/TV results (fig. 2, 3). Sp results as shown in fig. 4, the significance of the model group (0.3102 ± 0.02452) was increased (P <0.001) compared to the normal group (0.2838 ± 0.02157), and the significance of the sodium hyaluronate group (0.3836 ± 0.02649) and TVN (0.5mg/kg) group (0.3320 ± 0.03286) and (1mg/kg) group (0.3059 ± 0.02456) was decreased (P <0.001) compared to the model group. These results indicate that after ACLT molding, knee joint instability is caused, and the microstructure of the subchondral bone changes in the early stage, mainly cartilage destruction, which is manifested in bone remodeling of the subchondral bone. TVN (0.5,1mg/kg) can play a role in resisting bone resorption to inhibit bone remodeling of subchondral bone, relieve bone destruction and resorption, and protect bone structure of the subchondral bone, thereby playing a role in protecting articular cartilage.
Example 4 safranine fast green and toluidine blue staining to assess the protective effect of TVN on subchondral bone
The 4% paraformaldehyde fixed specimen was decalcified by changing to 10% EDTA for 4 weeks. After decalcification, the slices are dehydrated step by using ethanol with different concentrations, then paraffin embedding is carried out, and continuous longitudinal section sampling is carried out, wherein the section thickness is about 5 mu m. Each group randomly selected 6 specimens for sectioning, each specimen sectioned into 6 pieces. The resulting sections were dewaxed with xylene and then hydrated with a gradient of ethanol to remove residual xylene. Staining with safranine fast green and toluidine blue, then dehydrating the sections with gradient ethanol, then permeabilizing with xylene, and finally mounting with neutral gum. Panoramic scanning is performed using a slice scanner. The safranin can be combined with proteoglycan to show red color, and safranin fast green staining can visually reflect the changes of articular cartilage and subchondral bone structures, and the results are shown in figure 5, wherein the subchondral bone surface of a normal group is smooth, the boundary between cartilage and subchondral bone is clear, the tide line is complete, and the joint gap is large. And the color of the model group becomes light, the surface of the model group is festered and uneven, cracks appear, cell clusters appear irregularly, and the joint space is obviously narrowed. The TVN (0.5,1mg/kg) administration group was able to significantly improve these changes compared to the model group, while there was no significant difference between the sodium hyaluronate group and the TVN (0.5,1mg/kg) administration group. Toluidine blue staining reflects mainly glycosaminoglycan changes in the cartilage matrix, consistent with the results obtained with safranin fast green (fig. 6). Finally, scoring the image according to an OARSI (Osteoarthritis Research Society International) cartilage histopathology scoring system, and grading and evaluating the damage degree, wherein the scoring grade is as follows:
0 minute: normal cartilage
0.5 min: intact cartilage but loss of proteoglycans
1 minute: without cartilage loss but with fibrillation
And 2, dividing: vertical cracking and skin panel loss
And 3, dividing: the calcified layer lesion accounts for 1-25% of the whole articular surface
And 4, dividing: the calcified layer lesion accounts for 25-50% of the whole articular surface
And 5, dividing: the calcified layer lesion accounts for 50-75% of the whole articular surface
6 min: calcified layer lesion > 75%
The results are shown in FIG. 7: the OARSI score of the normal group is 0.5 +/-0.4472, the model group is 4.833 +/-0.7528, the score of the model group is obviously increased compared with the normal group (P <0.001), and the score of the model group is also obviously increased compared with the score of the sodium hyaluronate group (3.000 +/-0.8944). The TVN (0.5mg/kg) group scores 3.167 + -0.7528, and the TVN (1mg/kg) group scores 2.833 + -0.7528, and the TVN (1mg/kg) group scores significantly lower than the model group without significant difference with the sodium hyaluronate group. These results show that joint cavity injection of TVN can significantly improve cartilage degradation of ACLT model-making rats and reduce cartilage damage, thereby delaying the progression of osteoarthritis.
Example 5 immunohistochemical evaluation of the inhibitory Effect of TVN on cartilage matrix degradation
Immunohistochemical staining of the above sections was performed by incubating with 3% hydrogen peroxide for 5min, then soaking in PBS, further incubating with 10% goat serum at room temperature for 10min, adding MMP13(DF6494, 1:100), collagen II (ab34712, 1:100) primary antibody, and incubating overnight at 4 ℃. The next day, the cells were washed 3 times with PBS, and then biotin-labeled secondary antibody was added dropwise and incubated at room temperature for 30 min. Washing with PBS, labeling with horseradish peroxidase for 30min, washing with PBS, DAB developing, washing, counterstaining with hematoxylin, and sealing. The staining results of MMP13 are shown in fig. 8, and the protein expression of MMP13 in the model group was significantly increased as compared with the normal group, and also significantly increased as compared with the sodium hyaluronate group and TVN (0.5,1mg/kg) administration group. As a result of staining with Collagen II, as shown in FIG. 8, the protein expression in the model group with Collagen II was significantly reduced as compared with the normal group, and also significantly reduced as compared with the sodium hyaluronate group and TVN (0.5,1mg/kg) administration group. Collagen II is the major component of cartilage matrix (ECM) composition, and MMP13 is the most major metal matrix enzyme degrading Collagen II. These results show that intra-articular injection of TVN is effective in inhibiting degradation of ECM, and thus, in inhibiting osteoarthritis progression.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110080192.1A CN112791080B (en) | 2021-01-21 | 2021-01-21 | Application of resveratrol dimer TVN in preparation of medicine for treating osteoarthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110080192.1A CN112791080B (en) | 2021-01-21 | 2021-01-21 | Application of resveratrol dimer TVN in preparation of medicine for treating osteoarthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112791080A true CN112791080A (en) | 2021-05-14 |
| CN112791080B CN112791080B (en) | 2022-11-08 |
Family
ID=75810970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110080192.1A Active CN112791080B (en) | 2021-01-21 | 2021-01-21 | Application of resveratrol dimer TVN in preparation of medicine for treating osteoarthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112791080B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113967199A (en) * | 2021-11-29 | 2022-01-25 | 河南省洛阳正骨医院（河南省骨科医院） | Application of resveratrol-polylactic acid long-acting nano microspheres in preparation of medicines for resisting osteoarthritis |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1566054A (en) * | 2003-06-27 | 2005-01-19 | 中国医学科学院药物研究所 | Resveratrol oligo cattail compounds, its manufacturing process, pharmaceutical combination and uses thereof |
| CN102432620A (en) * | 2011-09-09 | 2012-05-02 | 南京大学 | Resveratrol tetramer compound, its preparation method and application |
| CN102440981A (en) * | 2010-10-15 | 2012-05-09 | 复旦大学 | Application of natural resveratrol dimer Pallidol compound in pharmacy |
| CN103275044A (en) * | 2013-06-14 | 2013-09-04 | 中国药科大学 | R type resveratrol oligomer as well as preparation method and blood sugar decreasing application thereof |
| CN109721579A (en) * | 2017-10-27 | 2019-05-07 | 中国医学科学院药物研究所 | The plain derivative of 7,8- dehydrogenation grapevine penta, its preparation method and pharmaceutical composition and purposes |
| CN109897021A (en) * | 2017-12-07 | 2019-06-18 | 中国医学科学院药物研究所 | The plain derivative of grapevine penta, its preparation method and pharmaceutical composition and purposes |
-
2021
- 2021-01-21 CN CN202110080192.1A patent/CN112791080B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1566054A (en) * | 2003-06-27 | 2005-01-19 | 中国医学科学院药物研究所 | Resveratrol oligo cattail compounds, its manufacturing process, pharmaceutical combination and uses thereof |
| CN102440981A (en) * | 2010-10-15 | 2012-05-09 | 复旦大学 | Application of natural resveratrol dimer Pallidol compound in pharmacy |
| CN102432620A (en) * | 2011-09-09 | 2012-05-02 | 南京大学 | Resveratrol tetramer compound, its preparation method and application |
| CN103275044A (en) * | 2013-06-14 | 2013-09-04 | 中国药科大学 | R type resveratrol oligomer as well as preparation method and blood sugar decreasing application thereof |
| CN109721579A (en) * | 2017-10-27 | 2019-05-07 | 中国医学科学院药物研究所 | The plain derivative of 7,8- dehydrogenation grapevine penta, its preparation method and pharmaceutical composition and purposes |
| CN109897021A (en) * | 2017-12-07 | 2019-06-18 | 中国医学科学院药物研究所 | The plain derivative of grapevine penta, its preparation method and pharmaceutical composition and purposes |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113967199A (en) * | 2021-11-29 | 2022-01-25 | 河南省洛阳正骨医院（河南省骨科医院） | Application of resveratrol-polylactic acid long-acting nano microspheres in preparation of medicines for resisting osteoarthritis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112791080B (en) | 2022-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20140106447A1 (en) | Compositions and methods for recruiting stem cells | |
| Boriani et al. | A novel technique for decellularization of allogenic nerves and in vivo study of their use for peripheral nerve reconstruction | |
| BRPI0818719B1 (en) | composition for treating joint disease | |
| Tang et al. | Icariin accelerates cartilage defect repair by promoting chondrogenic differentiation of BMSCs under conditions of oxygen‐glucose deprivation | |
| WO2021249420A1 (en) | Use of kadsura heteroclita (roxb.) craib agent in preparation of medicament for resisting rheumatoid arthritis | |
| EA030022B1 (en) | Use of pedf-derived polypeptides for treating osteoarthritis | |
| CN112791080A (en) | Application of resveratrol dimer TVN in the preparation of medicaments for the treatment of osteoarthritis | |
| US20230399353A1 (en) | Amino acid derivative of glucosamine stimulating extracellular matrix synthesis and pharmaceutical composition comprising the same | |
| Peng et al. | Combination of a human articular cartilage-derived extracellular matrix scaffold and microfracture techniques for cartilage regeneration: a proof of concept in a sheep model | |
| Amaniti et al. | Ropivacaine myotoxicity after single intramuscular injection in rats | |
| WO2011033306A1 (en) | Inhibition of tendon adhesions | |
| WO2023040853A1 (en) | Periosteum-bone complex for reconstructing soft tissue-bone immune repair environment and preparation method therefor | |
| CN117159534A (en) | Application of bilobalide in preparing medicine for treating arthritis | |
| WO2024255197A1 (en) | Use of matrix metalloproteinase inhibitor in preparation of drug for preventing or treating osteoarthritis cartilage injury | |
| CN115368386A (en) | Small molecule compound for preventing and treating osteoarthritis and application thereof | |
| JP6489487B2 (en) | Novel use for treating osteoarthritis with tetrapeptide-3 GEKG or pentapeptide-3 GEGF | |
| Xiao et al. | Porcine platelet lysates exert the efficacy of chondroregeneration and SMAD2-mediated anti-chondrofibrosis on knee osteoarthritis | |
| TWI660735B (en) | Use of a peptide having 4 or 5 amino acids for treating the degenerative joint disease | |
| CN116211914B (en) | Application of traditional Chinese medicine composition containing scorpion and centipede in preparation of medicine for preventing and/or treating osteoarthritis | |
| CN112043696B (en) | Application of IDO-1 inhibitor in preparation of medicine for treating osteoarthritis | |
| Guo et al. | Based on PI3K/Akt Signaling Pathway, the Effects of Gubi Decoction on Chondrocyte Proliferation, Apoptosis, and Expression of Inflammatory Factors in a Rat Model of Osteoarthritis | |
| CN110403925B (en) | Application of chemical small molecule 4-aminobiphenyl in prevention and treatment of osteoarthritis | |
| JP6489486B2 (en) | Novel use for treating osteoarthritis with pentapeptide / hexapeptide | |
| TWI641379B (en) | Use of a peptide having 5 or 6 amino acids for treating the degenerative joint disease | |
| KR20220165026A (en) | Composition for Protecting or Regenerating Cartilage containing Ginsenoside-Rb1 and Hydrogel, and Pharmaceutical Composition for Preventing or Treating Degenerative Arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |